Canada markets closed

Hemostemix Inc. (HEM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0650-0.0050 (-7.14%)
At close: 10:52AM EST
Full screen
Previous Close0.0700
Open0.0700
Bid0.0650 x 0
Ask0.0700 x 0
Day's Range0.0650 - 0.0750
52 Week Range0.0650 - 0.2100
Volume92,000
Avg. Volume37,504
Market Cap5.836M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateMar 25, 2024 - Mar 30, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

    Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results today.The publication highlights the results of no option critical limb ischemia patients who started the clinical trial with an ulcer, comparing wound healing, amputation, and mortality between the patien

  • Newsfile

    Hemostemix Clarifies its October 3, 2023 News Release

    Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125. The Company closed the financing in the amount of $320,385 with the issuance of 2,669,875 units. In connection with that Offering, the Corporation paid eligible finders aggregate fees of $5,750.40 in cash ...

  • Newsfile

    Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease

    Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP-01 as a treatment for heart disease (ischemic and non-ischemic dilated cardiomyopathy), which demonstrates ACP-01 regenerates and improves cardiac function by up to 24.1% at 12 months in ischemic cardiomyopathy, ...